To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea
| Status: | Completed |
|---|---|
| Conditions: | Cosmetic |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/21/2019 |
| Start Date: | December 12, 2017 |
| End Date: | September 28, 2018 |
A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Taro Product to RLD, and Both Active Treatments to a Placebo Control in the Treatment of Moderate Facial Rosacea
To demonstrate the superiority of the efficacy of the test and reference products over that
of the placebo control in the treatment of moderate facial rosacea.
of the placebo control in the treatment of moderate facial rosacea.
A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group study, comparing
test and reference products and both active treatments to a placebo control in the treatment
of Moderate Facial Rosacea.
test and reference products and both active treatments to a placebo control in the treatment
of Moderate Facial Rosacea.
Inclusion Criteria:
- Healthy male or non-pregnant female aged ≥ 18 with a clinical diagnosis of facial
rosacea.
- Subjects must have provided IRB approved written informed consent.
Exclusion Criteria:
- Female Subjects who are pregnant, nursing or planning to become pregnant during study
participation.
- Subjects who have used estrogens or oral contraceptives for less than 3 months prior
to baseline; use of such therapy must remain constant throughout the study.
We found this trial at
1
site
Click here to add this to my saved trials
